Tracy Cunningham
Chief Tech/Sci/R&D Officer at AMRYT PHARMA PLC
Tracy Cunningham active positions
| Companies | Position | Start | End |
|---|---|---|---|
| AMRYT PHARMA PLC | Chief Tech/Sci/R&D Officer | 2020-03-31 | - |
| Health Research Board | Director/Board Member | - | - |
Career history of Tracy Cunningham
Former positions of Tracy Cunningham
| Companies | Position | Start | End |
|---|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | - | - |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | 2022-06-26 | - |
| Corporate Officer/Principal | 2020-03-31 | 2022-06-26 |
Training of Tracy Cunningham
| Royal College of Surgeons | Undergraduate Degree |
Statistics
International
| United Kingdom | 4 |
| Ireland | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
| Government | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Private companies | 3 |
|---|---|
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
| Health Research Board | Government |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Tracy Cunningham
- Experience
